S
ystemic inflammatory response syndrome (SIRS) accompanies tissue trauma or infection. When severe, SIRS contributes to critical illness requiring intensive medical care. Host immune responses may become dysregulated in the hours or days after severe infection, and extensive research has focused on possible therapies in this setting. Implementation of "sepsis bundles" has been effective in reducing mortality through goal-directed early treatments (1) . Adjunctive therapies are required to address the high mortality of severe sepsis. Acetyl salicylic acid (ASA; also referred to as aspirin) could have beneficial effects in systemic inflammation accompanying the tissue injury of trauma or severe infection.
Because of its antiplatelet effects and prevention of thrombosis complicating vascular disease, ASA is one of the most widely used drugs worldwide (2) via irreversible acetylation of platelet cyclo-oxygenase. Activated platelets play a complex role in sepsis pathogenesis that may possibly be downregulated by ASA (3) . Low doses of ASA also have been shown to have both anti-inflammatory and pro-inflammation resolution effects via induction of aspirintriggered lipoxins (ATL) and subsequent influences on numerous mechanisms involved in the inflammatory cascade (4, 5) .
In the past three decades, several in vivo and animal models of sepsis have been interrogated to assess the impact of ASA or nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical interest in NSAIDs (6, 7) culminated in a randomized clinical trial of ibuprofen in patients with sepsis that showed no statistically significant reduction in mortality, although the study size had inadequate power to detect 35% relative reduction in mortality (8) . A subsequently reported analysis of the small subgroup of patients with sepsis and hypothermia suggested a mortality benefit with ibuprofen (9); however, post hoc subgroup analyses of this kind are known to identify patterns that are often misleading when subject to later randomized testing (10) .
Given the minimal cost of ASA, it is opportune to reconsider potential survival benefits associated with ASA use in intensive care unit (ICU) patients with SIRS. Using data derived from a large cohort of ICU patients from a single institution, we sought to determine whether ASA Objective: Low doses of acetyl salicylic acid, acting through 15-epi-lipoxin A4, have been shown to be anti-inflammatory in human studies. The manifold effects of acetyl salicylic acid on human physiology potentially may benefit patients with the systemic inflammatory response syndrome after sepsis or tissue trauma. We sought to determine whether acetyl salicylic acid administration at the time of development of systemic inflammatory response syndrome is associated with reduced mortality.
Design: retrospective cohort study of consecutive intensive care unit admissions between April 2000 and November 2009.
Setting: Australian tertiary referral center.
Patients: Seven-thousand nine-hundred forty-five intensive care unit admissions examined.
Measurements and Main Results: The probability of in-hospital death during admissions in which individuals were identified as having systemic inflammatory response syndrome or sepsis was analyzed according to whether they were administered acetyl salicylic acid. Propensity analysis that matched all patients for their probability of being prescribed acetyl salicylic acid was undertaken. Among 5523 patients with a first episode of systemic inflammatory response syndrome, 2082 were administered acetyl salicylic acid in a 24-hr period around the time of systemic inflammatory response syndrome recognition. Propensity analysis showed a 10.9% mortality for acetyl salicylic acid users and 17.2% mortality in the propensity-matched nonusers (absolute risk dif ference 26.2%; 95% confidence interval 29.5% to 23.5%). Propensity matching also found that acetyl salicylic acid admin istration was associated with increased risk of renal injury (6.2% vs. 2.9%; absolute risk difference 13.3%; 95% confidence inter val 2.5% to 5.0%). In the 970 patients with proven sepsis, acetyl salicylic acid administration was associated with a lower mortality (27.4% vs. 42.2%; absolute risk difference 214.8%; 95% confi dence interval 218.9% to 28.6%) after propensity matching. This quasi-experimental study cannot establish a causal association between acetyl salicylic acid and death from systemic inflammatory response syndrome or sepsis. Unrecognized confounders may remain but numerous covariates are included in the analyses.
Conclusions: Our study shows a strong association between acetyl salicylic acid and survival in intensive care unit systemic inflammatory response syndrome and sepsis patients. The effect of acetyl salicylic acid treatment on mortality of patients with systemic inflammatory response syndrome and sepsis needs to be evaluated with prospective randomized intervention studies. Key WOrDS: aspirin; low-dose; propensity analysis; sepsis; survival; systemic inflammatory response syndrome acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis administration at the time of development of SIRS is associated with reduced mortality. We have estimated the association between ASA and mortality in SIRS and sepsis patients, controlling for potential confounding effects of a large number of covariates using propensity analysis. Patient demographics, in-hospital survival status, and comorbidities, including history of diabetes, ischemic heart disease risk factors and events, and renal, liver, and gastrointestinal disease, were extracted. The ICU admission diagnoses were used to determine whether sepsis (respiratory, urinary, other infection, or gastrointestinal perforation with peritonitis) and local bleeding (gastrointestinal, intracranial, and respiratory, among others) were present. The four parameters that contribute to SIRS diagnosis were recorded and all patients with SIRS, as defined by the Bone criteria (11), were included in the study. When at least two SIRS criteria were met, evidence of current ASA administration was sought by examining drug administration records for the 24-hr period around the time of SIRS detection. Any NSAID use at any time during patient ICU stay was also analyzed. The ICU patients without SIRS were excluded.
MATERIALS AND METHODS
All patients displaying SIRS were included in the analysis with the primary outcome being in-hospital death. Renal injury, defined as a two-fold increase in creatinine over baseline as per the RIFLE criteria, (12) and bleeding were also recorded.
Choice of Covariates. The aim of this study was to control as much as possible for the variables that confound the measured effect of ASA on mortality in our cohort. To achieve this, we performed a propensity analysis aiming to match ASA users and nonusers with respect to covariates that correlate with risk of death. This is intended to produce two groups that are comparable except for ASA use.
However, we wanted to avoid including covariates that are part of the causal pathway to death, for example, shock requiring vasopressor use in ICU. Hence, variables chosen for inclusion in the propensity analysis had to be available at the time of SIRS diagnosis. These variables were those that related to: patient demographics; past cardiac, liver, or renal disease; cardiac surgery, ischemic heart disease, and associated risk factors; factors that may strongly influence against ASA use including bleeding in ICU; and disease severity on admission (Acute Physiology and Chronic Health Evaluation [APACHE] II score) ( Tables 1 and 2 ).
Unadjusted Results. Description of the baseline characteristics of the ASA user and nonuser group compared baseline continuous characteristics, such as age and APACHE II score, using the Mann-Whitney U tests for non-normally distributed data and t tests for normally distributed data. Fisher exact tests were used for comparing binary characteristics and the crude rates of mortality in the ASA user and ASA nonuser groups (Stata version 11; StataCorpLP, College Station, TX).
Propensity Matching. Propensity analysis was performed using the command "psmatch2" in Stata version 11. Propensity-matched ASA users and nonusers were selected from the total cohort using the Mahalanobis (13) matching method without replacement. Standard errors of the estimates were determined by bootstrapping. The Mahalanobis matching algorithm randomly draws suitable matches (those with the closest propensity scores and other covariate characteristics to the ASA users) from the nonuser group. A caliper of 0.05 was applied (only potential matches with a propensity score of the aspirin-user case propensity score  0.05 could be proposed in the match) to ensure the matched ASA nonuser controls had similar propensity scores as the ASA users.
The method described led to inclusion of 1445 of the 2082 eligible ASA users in the analysis, with 637 rejected on the grounds of inability to find a close propensity match. The 1445 ASA users were matched with 1445 ASA nonusers (1:1 match).
Multivariable logistic regression was performed using the same predictive variables of interest (Table 3 ). All variables included in the propensity analysis were included in the logistic model. There was no forward or backward stepwise selection process. All observations that met inclusion criteria (first episode of SIRS) were included in the logistic regression analysis, that is, there was no matching process as occurred with the propensity analysis.
Survival Analysis. Comparison of ICU survival according to ASA exposure was performed on the two groups selected by the propensitymatching algorithm. Analysis of the effect of ASA was assessed using the Cox regression method and the proportional hazard assumption. The validity of the proportional hazard assumption was tested using Schoenfeld residuals after fitting the proportional hazard model.
RESULTS
The study included all 7,945 ICU admissions from the period April 2000 to November 2009. From these, 6,131 met the inclusion criteria of having SIRS. Of these, 608 were repeat admissions with SIRS and were therefore excluded, leaving 5,523 patients in the analysis; 2,082 pa tients were administered ASA within 24 hrs of onset of SIRS, of whom 195 died in hospital. Of the remaining 3,441, in-hospital death occurred in 687. The ASA dose administered was 150 mg in 96% of patients, and 382 were administered NSAIDs during their ICU stay (217 received ASA as well). Table 1 shows the characteristics of the ASA user and ASA nonuser groups before propensity matching of the two groups.
Primary Outcome: Effect of ASA on Mortality After Propensity Matching
The ASA group had a 10.9% in-hospital mortality compared with 17.2% in the nonusers (absolute risk difference 6.2%; 95% CI 9.5% to 3.5%) after propensity matching. The selected matched nonuser group and ASA group were similar in their distribution of covariates and their propensity scores, as shown in Table 2 .
The effect of ASA exposure was observed throughout the patient admission, as shown in the survival analysis (Fig. 1) . The estimated hazard ratio for death in the ASAexposed group was 0.43 (p  .001). Test of proportional hazards found no significant change in the hazard ratio over time (p  .1); however, there is a trend toward reduced effect after 20 days (480 hrs). Table 3 shows the results, with a number of covariates having an association with the outcome of death even after conditioning on other covariates, with APACHE II score and history of bleeding being associated with higher mortality, whereas ASA use was associated with lower mortality independently of coronary artery surgery, which was also associated with lower mortality.
Sensitivity to Method: Logistic Regression

Reducing the Effect of Extreme Propensity Scores Via Propensity Range Narrowing
It has been argued that studies should treat carefully those individuals whose propensity scores are strongly discordant with their management (for example, people who are not using ASA but have a history of myocardial infarction). These people may be especially prone to hidden confounders (14) . Hence, in this study we examined the effect of narrowing the group for analysis to those with more central propensity scores. Table 4 shows that excluding the more extreme propensity values slightly reduced the estimated effect of ASA on mortality; however, it remained significant.
Results of Matching Propensity Scores for ASA for Other Outcomes
Renal Injury. Crude analysis showed that 6.4% of ASA users had development of renal impairment, compared with 3.2% of controls. After propensity matching, ASA users had a 6.2% rate and controls had a 2.9% rate of renal impairment (absolute risk difference 3.3%; 95% CI 2.5%-5.0%).
Bleeding. Here, propensity analysis showed the ASA-user bleeding rate was lower, at 8.8%, vs. 17.6%, for the matched nonuser group (absolute risk difference 8.8%, 95% CI 11.1% to 7.3%).
Assessment of the Association of Mortality and ASA in Patients With Sepsis
Of the 7,945 patients in the study, 1,020 had an episode of sepsis defined not on microbiological evidence, because this was not captured by the electronic database but on the basis of ICU admission diagnoses of respiratory, urinary, other infection, or gastrointestinal perforation with peritonitis. This definition will underestimate the number of patients in the cohort with sepsis, because it will exclude patients with development of sepsis in the ICU. Fifty of these events were repeat admissions for sepsis and were excluded, leaving 970 patients for analysis. Propensity analysis was performed exactly as described for SIRS patients. Of these, 165 patients had used ASA.
The crude in-hospital mortality rates in the ASA user and nonuser groups were 25.5% and 26.3%, respectively. After propensity matching, 30 ASA users were excluded from the analysis because of inability to match propensity scores. The remaining 135 were matched with 135 control nonusers. After propensity matching, the mortality in the ASA user and nonuser groups was 27.4% vs. 42.2% (absolute risk difference 14.8%; 95% CI 18.9% to 8.6%). Hence, the observed proportional change in mortality was similar for the sepsis group and SIRS group.
DISCUSSION
The goal of identifying a reliable intervention for sepsis has exerted drug developers and clinical trialists for at least two generations. Finding a cheap agent that could safely reduce the high mortality of sepsis, even if the effect were relatively small, would represent a great advance in treatment of critical illness.
We have shown a significant difference in mortality in ICU patients who were administered low-dose ASA at the time of the development of SIRS and sepsis compared with those not using ASA in this period. The magnitude and direction of effect estimated by the propensity analyses and the multivariable logistic regression are consistent. Being quasi-experimental, this study cannot establish a causal association between ASA and death from SIRS or sepsis. Despite efforts to adjust for confounding factors, the difference in mortality between ASA users and nonusers could potentially be attributable to residual confounding. Before propensity matching, the cohort of ASA-treated SIRS patients appeared to be sicker than those not prescribed ASA in ICU. For example, they had longer ICU stays on average and were more likely to be intubated, but they had lower APACHE II scores. However, this was controlled for in the matching with the numerous covariates based on demographics, status at the time of admission, and medical history, including factors that would strongly influence for and against ASA use. Propensity matching was effective in matching for all covariates selected as potential confounders. We achieved excellent matching in propensity scores in this study; however, this was at the expense of excluding some subjects, both ASA users and nonusers. Despite good matching for known confounders, it remains possible that there exists a treatment bias, with people less likely to die being more likely to be exposed to ASA, and that this effect cannot be captured by APACHE II score, medical history, and demographic matching.
A potential illustration of this treatment bias may exist in the observed, but seemingly paradoxic, reduction in bleeding in ASA-treated patients. It may be that patients with bleeding had their ASA therapy stopped. A more predictable positive association between ASA therapy and renal impairment is suggested by our analysis.
We have been forced to concentrate our analysis on patients with SIRS, because although the available database accurately indicated the first time when patients had SIRS in ICU, the absence of microbiological data could not rule in or rule out sepsis in every case. A smaller group of patients with APACHE III admission sepsis diagnoses were analyzed, showing the same nature of benefit of ASA. It is obvious that the inflammatory pathways that mediate SIRS and sepsis are indistinguishable. The patients involved in this study did not have mild SIRS, with mean APACHE II scores of 17 and overall mortality of 16%. The patients in the ASA group of this study had been using ASA before admission to ICU, so any beneficial effects cannot be ascribed to acute changes mediated by this drug.
There has been a consistent beneficial effect of ASA or NSAIDs on mortality in the setting of sepsis in animal studies (15) (16) (17) (18) , the failed randomized controlled trial (in which a nonsignificant 3% lesser mortality was observed in the ibuprofen group) (8) , and this current observational cohort. Hence, we must also consider that a true effect of ASA on mortality in the setting of SIRS and sepsis may exist. It is interesting to speculate on the potential mechanisms for this.
ASA and NSAIDs act on numerous pathways involved in the sepsis-induced inflammatory cascade. Intrinsic to the beneficial effects of ASA is its ability to trigger the synthesis of 15-epi-lipoxin A4 (ATL), which in turn increases nitric oxide synthesis through endothelial nitric oxide synthase and inducible nitric oxide synthase (19) . An ASA dose as small as 75 mg has been shown in the human skin blister model to stimulate ATL and reduce acute inflammation via a nitric oxidedependent pathway, which inhibits leukocyte endothelial cell interactions and decreases polymorph neutrophil numbers in blister fluid (20) . ATL also acts to reverse the polymorphonuclear neutrophil apoptotic arrest found in sepsis, reducing the ongoing elaboration of proinflammatory cytokines (21) . Finally, ALT reduces tumor necrosis factor release by T cells (22) . ASA is unique among the NSAIDs in these actions because it alone directly acetylates the cyclo-oxygenase-2 site in endothelial and epithelial cells to induce the formation of ATL (4) .
Another pathway by which relatively low doses of ASA may potentially act to improve sepsis outcomes is through inhibition of nuclear factor kappa-B. ASA inhibits the cellular kinase complex IKK, preserving nuclear factor kappa-B in an inactive state (23, 24) . This results in reduced transcription of proinflammatory enzymes, including tumor necrosis factor, interleukin-6 (23), and cyclo-oxygenase (25) , as well as tissue factor (26) . Higher doses of ASA are required than those that trigger ATL. The doses shown in vitro to inhibit IKK are in the range of 1-5 mM (24) , but the lower range of doses in humans required to produce this effect has not been determined.
Cellular and organ level benefits of ASA and NSAIDs have been identified that would be therapeutic in septic patients. Lipopolysaccharide-mediated (27) and a-toxin-mediated (28) depression in cardiac contractility can both be reversed by NSAIDs. Pulmonary vasculature abnormalities are improved (29) . Numerous whole animal endotoxemia models showed improved outcomes with ASA (17) or ibuprofen (18, 30) . Recent observational studies describe improved clinical outcomes in ICU patients using ASA prehospitalization. A single-center study showed reduced mortality with use of ASA in ICU patients with sepsis (31). Antiplatelet agent-treated patients with community-acquired pneumonia were also shown to have reduced length of hospitalization (32) . A singlecenter study of ICU patients showed reduction in acute lung injury in those using antiplatelet therapy (95% using ASA) before hospitalization (33) . A larger multicenter study of more heterogeneous ICU populations showed a reduction in acute lung injury but not mortality in ASA-treated patients on univariate analysis (34) . Whereas the effect after stratification by propensity was not statistically significant, the observed effect size of ASA on acute lung injury measured was remarkably similar to that found in the current study. Our methodology did not involve stratifying, thus increasing the power of our analysis. Additionally, variables relating to comorbidities but not disease severity were used (34) in distinction to our study. Last, potentiation by ASA of the decreased rates of severe sepsis as well as acute lung injury in ICU patients treated before hospitalization with statins has been shown (35) . In our current series, we have insufficient non-ASA antiplatelet agent-treated patients to determine whether the observed reduction in mortality relates to antiplatelet or antiinflammatory actions.
With this study, we have shown a significantly lower mortality in ASA-treated ICU patients with SIRS and sepsis. Although the magnitude of the effect appears great, propensity analysis that includes the same wide range of factors as the multivariable analysis and shows the same effect increases our confidence in the result. The extent of the effect may be exaggerated by confounding that remains unadjusted by the propensity analysis. The investigators will use a current multinational study of low-dose ASA for the primary prevention of dementia and thromboembolic disease (ASPREE) (36) to determine whether ASA reduces the severity of infection. The suggested benefit of ASA shown in this study, if confirmed in randomized controlled trials, would be a major addition to the armamentarium used to redress the high mortality of sepsis.
